Tocilizumab was additionally purchased for the treatment of patients with coronavirus

State enterprise “Medical Procurement of Ukraine” has purchased 3,140 vials of Tocilizumab, which is used to help patients with COVID-19.

A total of 2,300 vials with a dosage of 200 mg/10 ml were purchased for UAH 21.3 million and 840 vials with a dosage of 80 mg/4 ml for UAH 3.06 million. The patented original drug was purchased directly from a Swiss manufacturing company.

By March 1, 2022, the drug “Tocilizumab” will be delivered to the warehouse of the logistics partner of the state enterprise “Medical Procurement of Ukraine”.

It should be recalled that this year the state enterprise “Medical Procurement of Ukraine” has already purchased Tocilizumab twice. Namely: 2784 vials with a dosage of 200 mg/10 ml and 5950 vials with a dosage of 80 mg/4 ml.

On December 9, 2021, the European Medicines Agency (EMA) approved the use of Tocilizumab for the treatment of patients with severe coronavirus disease.

On August 18, 2021, WHO recommended Tocilizumab for the treatment of severe cases of COVID-19. The conclusions were made on the basis of 27 clinical trials involving 10,000 patients.

Studies have shown that the use of Tocilizumab in patients with severe disease reduces mortality by 13% compared to standard treatment. In addition, the use of Tocilizumab reduces the need for connection to artificial lung ventilation by 28% among seriously ill patients and patients with a critical course of the disease, compared to standard treatment.